User profiles for Simeng Lin

Simeng Lin

Exeter IBD Research Group
Verified email at exeter.ac.uk
Cited by 1456

Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study

…, NM Heerasing, P Hendy, S Lin… - The lancet …, 2019 - thelancet.com
Background Anti-TNF drugs are effective treatments for the management of Crohn's disease
but treatment failure is common. We aimed to identify clinical and pharmacokinetic factors …

Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD

NA Kennedy, S Lin, JR Goodhand, N Chanchlani… - Gut, 2021 - gut.bmj.com
Objective Delayed second dose SARS-CoV-2 vaccination trades maximal effectiveness for
a lower level of immunity across more of the population. We investigated whether patients …

[HTML][HTML] Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with …

S Lin, NA Kennedy, A Saifuddin, DM Sandoval… - Nature …, 2022 - nature.com
Anti tumour necrosis factor (anti-TNF) drugs increase the risk of serious respiratory infection
and impair protective immunity following pneumococcal and influenza vaccination. Here we …

Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab

…, JR Goodhand, C Bewshea, R Nice, D Chee, S Lin… - Gut, 2021 - gut.bmj.com
Objective Antitumour necrosis factor (anti-TNF) drugs impair protective immunity following
pneumococcal, influenza and viral hepatitis vaccination and increase the risk of serious …

Adalimumab and infliximab impair SARS-CoV-2 antibody responses: results from a therapeutic drug monitoring study in 11 422 biologic-treated patients

N Chanchlani, S Lin, D Chee, B Hamilton… - Journal of Crohn's …, 2022 - academic.oup.com
Background and Aims Infliximab attenuates serological responses to SARS-CoV-2 infection.
Whether this is a class effect, or if anti-tumour necrosis factor [anti-TNF] level influences …

Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic

NA Kennedy, M Janjua, N Chanchlani, S Lin… - Gut, 2023 - gut.bmj.com
Objective Antitumour necrosis factor (TNF) drugs impair serological responses following
SARS-CoV-2 vaccination. We sought to assess if a third dose of a messenger RNA (mRNA)-…

[HTML][HTML] The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory …

…, JM Blanco, LA Roberts, CM Bewshea, R Nice, S Lin… - …, 2023 - thelancet.com
Background Patients with inflammatory bowel disease (IBD) treated with anti-TNF therapy
exhibit attenuated humoral immune responses to vaccination against SARS-CoV-2. The gut …

Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic

S Lin, LHS Lau, N Chanchlani, NA Kennedy, SC Ng - Gut, 2022 - gut.bmj.com
The COVID-19 pandemic has raised considerable concerns that patients with inflammatory
bowel disease (IBD), particularly those treated with immunosuppressive therapies, may have …

[HTML][HTML] Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS …

N Chanchlani, S Lin, C Bewshea… - The Lancet …, 2024 - thelancet.com
Background We sought to report the effectiveness of infliximab and adalimumab over the first
3 years of treatment and to define the factors that predict anti-TNF treatment failure and the …

Whole blood DNA methylation changes are associated with anti-TNF drug concentration in patients with Crohn's disease

S Lin, E Hannon, M Reppell, JF Waring… - Journal of Crohn's …, 2023 - academic.oup.com
Background and Aims Anti-tumour necrosis factor [TNF] treatment failure in patients with
inflammatory bowel disease [IBD] is common and frequently related to low drug concentrations. …